PL3383363T3 - Preparaty farmaceutyczne do stosowania miejscowego do leczenia stanów związanych z zapaleniem - Google Patents
Preparaty farmaceutyczne do stosowania miejscowego do leczenia stanów związanych z zapaleniemInfo
- Publication number
- PL3383363T3 PL3383363T3 PL16805522T PL16805522T PL3383363T3 PL 3383363 T3 PL3383363 T3 PL 3383363T3 PL 16805522 T PL16805522 T PL 16805522T PL 16805522 T PL16805522 T PL 16805522T PL 3383363 T3 PL3383363 T3 PL 3383363T3
- Authority
- PL
- Poland
- Prior art keywords
- pharmaceutical formulations
- related conditions
- treating inflammatory
- topical pharmaceutical
- topical
- Prior art date
Links
- 230000002757 inflammatory effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000000699 topical effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562260716P | 2015-11-30 | 2015-11-30 | |
US201662420987P | 2016-11-11 | 2016-11-11 | |
EP16805522.6A EP3383363B1 (en) | 2015-11-30 | 2016-11-23 | Topical pharmaceutical formulations for treating inflammatory-related conditions |
PCT/IB2016/057073 WO2017093857A1 (en) | 2015-11-30 | 2016-11-23 | Topical pharmaceutical formulations for treating inflammatory-related conditions |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3383363T3 true PL3383363T3 (pl) | 2021-05-31 |
Family
ID=57471943
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL16805522T PL3383363T3 (pl) | 2015-11-30 | 2016-11-23 | Preparaty farmaceutyczne do stosowania miejscowego do leczenia stanów związanych z zapaleniem |
Country Status (24)
Country | Link |
---|---|
US (2) | US20170152273A1 (pl) |
EP (2) | EP3831389A1 (pl) |
JP (1) | JP6725403B2 (pl) |
KR (1) | KR102106230B1 (pl) |
CN (1) | CN108366958A (pl) |
AU (1) | AU2016362668C1 (pl) |
BR (1) | BR112018010464B1 (pl) |
CA (1) | CA2949614C (pl) |
CY (1) | CY1123845T1 (pl) |
DK (1) | DK3383363T3 (pl) |
ES (1) | ES2858311T3 (pl) |
HK (1) | HK1257818A1 (pl) |
HU (1) | HUE053115T2 (pl) |
IL (1) | IL259693B (pl) |
MX (1) | MX2018006578A (pl) |
NZ (1) | NZ742208A (pl) |
PL (1) | PL3383363T3 (pl) |
PT (1) | PT3383363T (pl) |
RU (1) | RU2724053C2 (pl) |
SG (2) | SG10202112628UA (pl) |
SI (1) | SI3383363T1 (pl) |
TW (1) | TWI627974B (pl) |
WO (1) | WO2017093857A1 (pl) |
ZA (1) | ZA201802920B (pl) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10265265B2 (en) | 2007-03-15 | 2019-04-23 | Drug Delivery Solutions Limited | Topical composition |
US11524964B2 (en) | 2015-10-16 | 2022-12-13 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11512092B2 (en) | 2015-10-16 | 2022-11-29 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11780848B2 (en) | 2015-10-16 | 2023-10-10 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof |
SG11201802990RA (en) | 2015-10-16 | 2018-05-30 | Abbvie Inc | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11447506B2 (en) | 2016-05-09 | 2022-09-20 | Anacor Pharmaceuticals, Inc. | Crystal forms of crisaborole in free form and preparation method and use thereof |
MX2018013742A (es) * | 2016-05-09 | 2019-08-01 | Anacor Pharmaceuticals Inc | Formas cristalinas de crisaborol en forma libre, metodo de preparacion y uso de las mismas. |
WO2017203514A1 (en) * | 2016-05-26 | 2017-11-30 | Perrigo Api Ltd | Polymorphs of crisaborole and production processes therefor |
GB201701583D0 (en) | 2017-01-31 | 2017-03-15 | Drug Delivery Solutions Ltd | Topical composition |
WO2018224923A1 (en) * | 2017-06-05 | 2018-12-13 | Glenmark Pharmaceuticals Limited | Process for preparation of crisaborole |
US11129818B2 (en) | 2017-06-07 | 2021-09-28 | Arcutis Biotherapeutics, Inc. | Topical roflumilast formulation having improved delivery and plasma half life |
US12042487B2 (en) | 2018-11-16 | 2024-07-23 | Arcutis Biotherapeutics, Inc. | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors |
US12011437B1 (en) | 2017-06-07 | 2024-06-18 | Arcutis Biotherapeutics, Inc. | Roflumilast formulations with an improved pharmacokinetic profile |
US20200155524A1 (en) * | 2018-11-16 | 2020-05-21 | Arcutis, Inc. | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors |
US9895359B1 (en) * | 2017-06-07 | 2018-02-20 | Arcutis, Inc. | Inhibition of crystal growth of roflumilast |
US20210161870A1 (en) | 2017-06-07 | 2021-06-03 | Arcutis Biotherapeutics, Inc. | Roflumilast formulations with an improved pharmacokinetic profile |
US11534493B2 (en) | 2017-09-22 | 2022-12-27 | Arcutis Biotherapeutics, Inc. | Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents |
US10329311B1 (en) | 2017-12-21 | 2019-06-25 | Olon S.P.A. | Process for the preparation of crisaborole |
CN109985000B (zh) * | 2017-12-29 | 2022-09-02 | 苏州旺山旺水生物医药有限公司 | 克立硼罗微乳组合物 |
PL3737685T3 (pl) * | 2018-01-09 | 2023-10-02 | Halcyon Labs Private Limited | Sposób wytwarzania kryzaborolu i jego związków pośrednich |
US10597410B2 (en) | 2018-02-02 | 2020-03-24 | Dipharma Francis S.R.L. | Intermediates and process for the preparation of a crystalline form of a topical anti-inflammatory agent |
BR112020016144A2 (pt) * | 2018-02-09 | 2020-12-15 | Nestlé Skin Health Sa | Nemolizumabe no tratamento de dermatite atópica com escoriação moderada a grave |
EP3542788A1 (en) | 2018-03-19 | 2019-09-25 | MC2 Therapeutics Limited | Topical composition comprising calcipotriol and betamethasone dipropionate |
CN108210462A (zh) * | 2018-03-29 | 2018-06-29 | 苏州尚宜佳生物科技有限公司 | 一种克立硼罗局部缓释脂质体的制法与应用 |
CN108324724A (zh) * | 2018-04-10 | 2018-07-27 | 苏州芝宇生物科技有限公司 | 一种克立硼罗可溶性膜制剂的制法及其应用 |
CN110464702A (zh) * | 2018-05-09 | 2019-11-19 | 上海键合医药科技有限公司 | 一种克立硼罗的软膏剂及其制备方法 |
KR20210044191A (ko) | 2018-06-04 | 2021-04-22 | 아큐티스, 인크. | 로플루밀라스트 피부 침투 지연 시간의 개선 방법 및 제형 |
CN108992454B (zh) | 2018-06-20 | 2020-06-02 | 合肥医工医药股份有限公司 | 一种治疗皮肤炎症性疾病的复方药物组合物 |
CN108785379A (zh) * | 2018-06-26 | 2018-11-13 | 苏州尚宜佳生物科技有限公司 | 一种克立硼罗清凉缓释膜及其制备方法 |
CN108524648A (zh) * | 2018-06-26 | 2018-09-14 | 苏州尚宜佳生物科技有限公司 | 一种克立硼罗复合保健缓释膜及其制备方法 |
CN108938603A (zh) * | 2018-06-27 | 2018-12-07 | 苏州尚宜佳生物科技有限公司 | 一种缓释效果好的克立硼罗缓释膜及其制备方法 |
CN108785372A (zh) * | 2018-06-27 | 2018-11-13 | 苏州尚宜佳生物科技有限公司 | 一种克立硼罗燥湿利尿缓释膜及其制备方法 |
CN108926547A (zh) * | 2018-07-02 | 2018-12-04 | 苏州尚宜佳生物科技有限公司 | 一种粘贴效果好的克立硼罗缓释膜及其制备方法 |
CN108938602A (zh) * | 2018-07-02 | 2018-12-07 | 苏州尚宜佳生物科技有限公司 | 一种吸收效果好的克立硼罗缓释膜及其制备方法 |
CN108853062A (zh) * | 2018-07-04 | 2018-11-23 | 苏州尚宜佳生物科技有限公司 | 一种肤感克立硼罗缓释膜的制备方法 |
CN108853063A (zh) * | 2018-07-04 | 2018-11-23 | 苏州尚宜佳生物科技有限公司 | 一种透气效果好的克立硼罗缓释膜的制备方法 |
CN108853064A (zh) * | 2018-07-09 | 2018-11-23 | 苏州尚宜佳生物科技有限公司 | 一种防水透气克立硼罗缓释膜的制备方法 |
CN108653246A (zh) * | 2018-07-09 | 2018-10-16 | 苏州尚宜佳生物科技有限公司 | 一种防水效果好的克立硼罗缓释膜的制备方法 |
CN112384201A (zh) * | 2018-07-31 | 2021-02-19 | Mc2疗法有限公司 | 局部组合物 |
WO2020051230A1 (en) * | 2018-09-04 | 2020-03-12 | X-Rx, Inc. | Amorphous pharmaceutical compositions and uses thereof |
CN112770756A (zh) * | 2018-09-29 | 2021-05-07 | 苏州科睿思制药有限公司 | 一种Upadacitinib的晶型及其制备方法和用途 |
CN111217819B (zh) * | 2018-11-27 | 2021-05-14 | 杭州科巢生物科技有限公司 | 乌帕替尼的合成方法 |
MX2022003872A (es) * | 2019-09-30 | 2022-07-04 | Abbvie Inc | Tratamiento de afecciones espondiloartríticas y psoriásicas con upadacitinib. |
EP4140480A4 (en) * | 2020-04-23 | 2024-06-12 | Natural Medicine Institute Of Zhejiang Yangshengtang Co., Ltd. | DRUG COMBINATION AND USE |
KR20230025458A (ko) * | 2020-06-17 | 2023-02-21 | 카이메라 쎄라퓨틱스 인코포레이티드 | Irak 분해제 및 이의 용도 |
EP4199902A1 (en) * | 2020-08-20 | 2023-06-28 | Pfizer Inc. | Stable topical formulations of 1(r)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol |
CN112168774A (zh) * | 2020-11-04 | 2021-01-05 | 南京康川济医药科技有限公司 | 一种巴瑞克替尼乳膏及其制备方法和应用 |
WO2023138804A1 (en) * | 2022-01-20 | 2023-07-27 | Renata Pharmaceutical (Ireland) Limited | Sustained release pharmaceutical composition of upadacitinib |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4282216A (en) * | 1977-04-20 | 1981-08-04 | Johnson & Johnson | Topical anti-inflammatory drug therapy |
CA2597982C (en) | 2005-02-16 | 2014-07-08 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
SI2719388T1 (sl) * | 2006-02-16 | 2019-06-28 | Anacor Pharmaceuticals, Inc. | Majhne molekule, polnjene z borom, kot učinkovine proti vnetjem |
WO2009111676A2 (en) | 2008-03-06 | 2009-09-11 | Anacor Pharmaceuticals, Inc | Boron-containing small molecules as anti-inflammatory agents |
JP5745279B2 (ja) * | 2008-01-09 | 2015-07-08 | アナコール ファーマシューティカルズ,インコーポレイテッド | 抗炎症剤としてのホウ素含有小分子 |
MX2010009765A (es) | 2008-03-06 | 2013-07-12 | Anacor Pharmaceuticals Inc | Moleculas pequeñas que contienen boro como agentes anti-inflamatorios. |
WO2011094450A1 (en) | 2010-01-27 | 2011-08-04 | Anacor Pharmaceuticals, Inc | Boron-containing small molecules |
GB201402070D0 (en) * | 2014-02-07 | 2014-03-26 | Galapagos Nv | Pharmaceutical compositions for the treatment of inflammatory disorders |
-
2016
- 2016-11-23 KR KR1020187018210A patent/KR102106230B1/ko active IP Right Grant
- 2016-11-23 HU HUE16805522A patent/HUE053115T2/hu unknown
- 2016-11-23 BR BR112018010464-7A patent/BR112018010464B1/pt active IP Right Grant
- 2016-11-23 IL IL259693A patent/IL259693B/en unknown
- 2016-11-23 ES ES16805522T patent/ES2858311T3/es active Active
- 2016-11-23 SI SI201631089T patent/SI3383363T1/sl unknown
- 2016-11-23 SG SG10202112628UA patent/SG10202112628UA/en unknown
- 2016-11-23 AU AU2016362668A patent/AU2016362668C1/en active Active
- 2016-11-23 RU RU2018119295A patent/RU2724053C2/ru active
- 2016-11-23 PT PT168055226T patent/PT3383363T/pt unknown
- 2016-11-23 PL PL16805522T patent/PL3383363T3/pl unknown
- 2016-11-23 SG SG11201803728YA patent/SG11201803728YA/en unknown
- 2016-11-23 CN CN201680069997.3A patent/CN108366958A/zh active Pending
- 2016-11-23 WO PCT/IB2016/057073 patent/WO2017093857A1/en active Application Filing
- 2016-11-23 DK DK16805522.6T patent/DK3383363T3/da active
- 2016-11-23 EP EP20215322.7A patent/EP3831389A1/en active Pending
- 2016-11-23 EP EP16805522.6A patent/EP3383363B1/en active Active
- 2016-11-23 MX MX2018006578A patent/MX2018006578A/es unknown
- 2016-11-23 NZ NZ742208A patent/NZ742208A/en unknown
- 2016-11-25 CA CA2949614A patent/CA2949614C/en active Active
- 2016-11-28 JP JP2016229721A patent/JP6725403B2/ja active Active
- 2016-11-29 TW TW105139318A patent/TWI627974B/zh active
- 2016-11-30 US US15/364,347 patent/US20170152273A1/en not_active Abandoned
-
2018
- 2018-05-04 ZA ZA2018/02920A patent/ZA201802920B/en unknown
-
2019
- 2019-01-04 HK HK19100162.1A patent/HK1257818A1/zh unknown
- 2019-06-25 US US16/451,107 patent/US20190308994A1/en not_active Abandoned
-
2021
- 2021-02-25 CY CY20211100160T patent/CY1123845T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1257818A1 (zh) | 用於治療炎症相關病症的局部藥物製劑 | |
IL282304A (en) | Pharmaceutical preparations for local use | |
IL290823A (en) | Pharmaceutical preparations for combination therapy | |
IL268316B (en) | Pharmaceutical preparations for combined treatment | |
SG11201705093UA (en) | Composition for treating il-6-related diseases | |
HK1257665A1 (zh) | 用於治療線粒體疾病的新化合物 | |
IL249412A0 (en) | Topical formulations for protection against UV radiation | |
PL3524255T3 (pl) | Kompozycja do leczenia trądziku | |
HK1247827A1 (zh) | 局部治療組合物 | |
HK1231390A1 (zh) | 用於局部給藥的藥用組合物 | |
EP3275450A4 (en) | Pharmaceutical composition for preventing or treating inflammatory diseases, containinglactococcus chungangensis | |
GB201502845D0 (en) | Topical pharmaceutical formulation | |
EP3375443A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF RESPIRATORY DISEASES | |
GB201609968D0 (en) | Topical pharmaceutical formulation | |
EP3354271A4 (en) | Agent for treating arthrological diseases | |
SG11201708197QA (en) | Pharmaceutical composition for skin |